Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | TTI-622 |
Synonyms | |
Therapy Description |
TTI-622 is a fusion protein consisting of SIRPa fused to the human IgG4 Fc region, that binds to CD47 and blocks inhibitory signaling to macrophages, resulting in increased phagocytosis of tumor cells (Cancer Res 2018;78(13 Suppl):Abstract nr 2709). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
TTI-622 | PF07901801|PF 07901801|PF-07901801|Maplirpacept|TTI 622|TTI622 | CD47 Antibody 31 Immune Checkpoint Inhibitor 149 | TTI-622 is a fusion protein consisting of SIRPa fused to the human IgG4 Fc region, that binds to CD47 and blocks inhibitory signaling to macrophages, resulting in increased phagocytosis of tumor cells (Cancer Res 2018;78(13 Suppl):Abstract nr 2709). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03530683 | Phase I | TTI-622 | A Trial of TTI-622 in Patients With Advanced Relapsed or Refractory Lymphoma or Myeloma | Terminated | USA | 0 |